Back to Agenda
Session 6: COVID-19 Hot Topics: Rapid Responses of the RWE Community
Session Chair(s)
Marni Hall, PhD, MPH
VP & GM, Global Regulatory Science and Strategy
IQVIA, United States
Richard Forshee, PhD
Deputy Director, OBPV CBER
FDA, United States
This session provides examples of the role RWE plays to inform the pandemic response. Specific use cases including evaluation of the natural history of the disease, comparative studies of therapeutics, and establishment of a near real-time community reporting system. An emphasis will be placed on lessons learned from the need for rapid collaboration and adaptation.
Learning Objective : At the conclusion of this session, participants should be able to:
- List key uses for RWE in the COVID-19 pandemic
- Discuss representative COVID-19 pandemic RWD sources and their strengths and limitations
- Apply lessons learned from collaborative COVID-19 pandemic RWE partnerships to future activities
Speaker(s)
Speaker
Robert Ball, MD, MPH, MSc
FDA, United States
Deputy Director, Office of Surveillance and Epidemiology, CDER
Speaker
Patrick Ryan
Janssen Pharmaceuticals, Inc., United States
Head, Epidemiology Analytics
Speaker
Jeff Allen, PhD
Friends of Cancer Research, United States
President and Chief Executive Officer
Speaker
Nancy A Dreyer, PhD, MPH, FISPE
Dreyer Strategies LLC, United States
Founder
Have an account?